Trials / Active Not Recruiting
Active Not RecruitingNCT05117476
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 440 (estimated)
- Sponsor
- Cullinan Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLN-619 | Anti-MICA/MICB monoclonal antibody |
| DRUG | Pembrolizumab | Keytruda |
| DRUG | Paclitaxel | Taxane |
| DRUG | Carboplatin AUC 6 | Platinum compound |
| DRUG | pemetrexed | antifolate |
| DRUG | Datopotamab deruxtecan-dlnk (Dato-DXd) | TROP-2 antibody-drug conjugate (ADC) |
Timeline
- Start date
- 2021-10-29
- Primary completion
- 2026-03-01
- Completion
- 2026-06-01
- First posted
- 2021-11-11
- Last updated
- 2025-11-24
Locations
24 sites across 4 countries: United States, Australia, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05117476. Inclusion in this directory is not an endorsement.